HDAC8 and acute myeloid leukemia: This was exemplified by Zhang et al. [41], who provided evidence that inhibition of two histone deacetylases, HDAC8 and SIRT6, enhances the anti-leukemic effect of NAMPT inhibitor in AML with minimal toxicity to healthy cells.